Evidence map›Paper›PMID 38287325›Full record

ArticleJournal of biomedical science2024

FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors.

Hsin-Fang Tu, Yu-Jui Kung, Ling Lim, Julia Tao, Ming-Hung Hu, Michelle Cheng, Deyin Xing, T C Wu, Chien-Fu Hung

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. [Progress in the Immune Mechanism of Microwave Ablation Therapy for Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  5. Article
  6. Microwave Ablation Combined with Flt3L Provokes Tumor-Specific Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hsin-Fang TuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Yu-Jui KungJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Ling LimDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Julia TaoDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Ming-Hung HuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Michelle ChengDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Deyin XingDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
T C WuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA. chung2@jhmi.edu.ORCID http://orcid.org/0000-0001-9170-7797
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of SalmonellaR21DE029910 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$450k
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccineR21CA234516 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$421k
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancerR21CA256020 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2021 to 2022
$417k
NCI NIH HHS 1R21CA234516-01A1NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA237067NCI NIH HHS R01CA237067NCI NIH HHS R21 CA234516NCI NIH HHS R21 CA256020NCI NIH HHS R21CA256020NCI NIH HHS R21DE029910-01NIDCR NIH HHS R21 DE029910
6 · The paper itself

Abstract

backgroundPrevious research in FMS-like tyrosine kinase 3 ligands (FLT3L) has primarily focused on their potential to generate dendritic cells (DCs) from bone marrow progenitors, with a limited understanding of how these cells affect CD8 T cell function. In this study, we further investigated the in vivo role of FLT3L for the immunomodulatory capabilities of CD8 T cells.

methodsAlbumin-conjugated FLT3L (Alb-FLT3L) was generated and applied for translational medicine purposes; here it was used to treat naïve C57BL/6 and OT1 mice for CD8 T cell response analysis. Syngeneic B16ova and E.G7ova mouse models were employed for adoptive cell transfer to evaluate the effects of Alb-FLT3L preconditioning of CD8 T cells on tumor progression. To uncover the underlying mechanisms of Alb-FLT3L modulation, we conducted bulk RNA-seq analysis of the CD44

resultsCD44

conclusionsThese findings provide critical insight and support the therapeutic potential of Alb-FLT3L as an immune modulator in preconditioning of naïve CD8 T cells for cancer immunotherapy.

Indexed as

CD8-Positive T-LymphocytesNeoplasmsAnimalsDendritic CellsInterferonsMembrane ProteinsMiceMice, Inbred C57BLflt3 ligand proteinInterferonsMembrane ProteinsAlb-FLT3LCD44high CD8 T cellsVirtual memory CD8 T cells

Identifiers

PMID38287325
PMCPMC10826030
OpenAlexW4391315612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.